Michael Lynch, senior director of product management at IQVIA, provides an Expert View on the benefits of adopting a flexible and scalable approach to data management in the life sciences, using artificial intelligence (AI).
The life sciences landscape has adapted in tandem with data management solutions over the past several years, attracting significant investment. However, these solutions lack the ability to rapidly address and complement existing pain points and previous investments with the latest technological innovations.
Previous data management investments, whether lacking in specific requirements or enterprise needs, often appear dated and rigid shortly after implementation. Unfortunately, due to the cost of investment, many organizations often allow this software to dictate the next information technology investment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze